Axsome Therapeutics, Inc. (AXSM): Price and Financial Metrics
GET POWR RATINGS... FREE!
AXSM Stock Price Chart Interactive Chart >
AXSM Price/Volume Stats
| Current price | $65.91 | 52-week high | $90.00 |
| Prev. close | $66.54 | 52-week low | $50.05 |
| Day low | $65.20 | Volume | 175,756 |
| Day high | $66.65 | Avg. volume | 340,390 |
| 50-day MA | $58.70 | Dividend yield | N/A |
| 200-day MA | $69.04 | Market Cap | 2.48B |
Axsome Therapeutics, Inc. (AXSM) Company Bio
Axsome Therapeutics Inc. focuses on developing therapies for the management of pain, neurological disorders, and other central nervous system. The company was founded in 2012 and is based in New York City, New York.
Latest AXSM News From Around the Web
Below are the latest news stories about Axsome Therapeutics Inc that investors may wish to consider to help them evaluate AXSM as an investment opportunity.
Axsome (AXSM) Plans NDA Filing for Fibromyalgia Drug in 2022Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA for AXS-14, which is being developed as a treatment of fibromyalgia. The company will file an NDA in the fourth quarter of 2022. |
Axsome Therapeutics Targets Submission Of US Application For Fibromyalgia Candidate By 2022After a pre-NDA meeting with FDA, Axsome Therapeutics Inc (NASDAQ: AXSM) has announced its plan to submit a marketing application seeking approval for AXS-14 to manage fibromyalgia. The submission is currently anticipated in the fourth quarter of 2022, pending completion of manufacturing and other activities related to the product candidate. AXS-14 has completed two positive placebo-controlled trials, a Phase 3 and a Phase 2 trial, which will be included in the submission. Fibromyalgia is a chro |
Axsome Therapeutics Announces Planned NDA Submission for AXS-14 for the Management of FibromyalgiaSubmission anticipated in 4Q 2022 NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced its plan to submit a New Drug Application (NDA) for AXS-14 for the management of fibromyalgia following a pre-NDA meeting with the U.S. Food and Drug Administration (FDA). AXS-14 (esreboxetine) is a novel, oral, potent, and highly selective norepi |
Why Is Axsome (AXSM) Up 14.7% Since Last Earnings Report?Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
2 Top Biotech Stocks to Buy for Summer 2021Progress in these companies' drug development pipelines should give shareholders plenty to look forward to. |
AXSM Price Returns
| 1-mo | 18.65% |
| 3-mo | 2.03% |
| 6-mo | -15.79% |
| 1-year | -14.83% |
| 3-year | 2,097.00% |
| 5-year | 939.59% |
| YTD | -19.10% |
| 2020 | -21.18% |
| 2019 | 3,565.25% |
| 2018 | -49.64% |
| 2017 | -17.04% |
| 2016 | -27.18% |
Loading social stream, please wait...